Vivani MedicalVANI
VANI
0
Funds holding %
of 7,398 funds
–
Analysts bullish %
Fund manager confidence
Based on 2024 Q4 regulatory filings by fund managers ($100M+ AUM)
133% more first-time investments, than exits
New positions opened: 7 | Existing positions closed: 3
15% more funds holding
Funds holding: 27 [Q3] → 31 (+4) [Q4]
0% more funds holding in top 10
Funds holding in top 10: 1 [Q3] → 1 (+0) [Q4]
0% more repeat investments, than reductions
Existing positions increased: 6 | Existing positions reduced: 6
1.99% less ownership
Funds ownership: 10.39% [Q3] → 8.4% (-1.99%) [Q4]
14% less capital invested
Capital invested by funds: $6.72M [Q3] → $5.77M (-$943K) [Q4]
75% less call options, than puts
Call options by funds: $24K | Put options by funds: $95K
Research analyst outlook
1 Wall Street Analyst provided 1 year price targets over the past 3 months
Low target
$4
292%
upside
Avg. target
$4
292%
upside
High target
$4
292%
upside
1 analyst rating
1 positive
100%
0 neutral
0%
0 negative
0%
HC Wainwright & Co. Yi Chen 38% 1-year accuracy 63 / 167 met price target | 292%upside $4 | Buy Reiterated | 26 Mar 2025 |
Financial journalist opinion
Based on 8 articles about VANI published over the past 30 days
Neutral
GlobeNewsWire
1 day ago
Vivani Medical Provides Business Update and Reports Fourth Quarter and Full Year 2024 Financial Results
Successful initial administration and full enrollment in first-in-human LIBERATE-1 ™ study of NPM-115 (exenatide implant) in obese and overweight subjects with top-line data expected in mid-2025

Neutral
GlobeNewsWire
5 days ago
Vivani Medical Announces $8.25M Private Placement Equity Financing
Financing strengthens balance sheet, extending expected runway into the second quarter of 2026 Enables accelerated development of NPM-139, Company's once or twice-yearly GLP-1 (semaglutide) implant under development for chronic weight management ALAMEDA, Calif., March 27, 2025 (GLOBE NEWSWIRE) -- Vivani Medical, Inc. (Nasdaq: VANI) (“Vivani” or the “Company”), a clinical-stage biopharmaceutical company developing miniature, ultra long-acting drug implants, today announced that it has entered into a securities purchase agreement to issue and sell an aggregate of 7,366,071 shares, each at a price of $1.12 per share, expected to result in gross proceeds of approximately $8.25 million in a private placement.

Neutral
GlobeNewsWire
6 days ago
Vivani Medical Announces Positive Preclinical Weight Loss Data for NPM-139 Semaglutide Implant, with Potential for Once-Yearly Dosing
NanoPortal™ technology successfully delivers semaglutide, the active ingredient in Ozempic®/Wegovy®, in a preclinical study with NPM-139 (semaglutide implant)

Neutral
Business Wire
1 week ago
Vivani Medical to Present at the Emerging Growth Conference on March 27, 2025
ALAMEDA, Calif.--(BUSINESS WIRE)--Vivani Medical, Inc. (NASDAQ: VANI) (“Vivani” or the “Company”), a clinical-stage biopharmaceutical company developing miniature, ultra long-acting drug implants, announced today that it will present at the Emerging Growth Conference on March 27, 2025. Vivani welcomes individual and institutional investors, along with advisors and analysts, to join its interactive presentation. This live online event will offer existing shareholders and the investment community.

Positive
Zacks Investment Research
2 weeks ago
What Makes Vivani Medical (VANI) a New Buy Stock
Vivani Medical (VANI) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).

Neutral
Business Wire
2 weeks ago
Vivani Medical Achieves First Implant and Full Enrollment in the First-in-Human Clinical Trial of GLP-1 Implant NPM-115 in Obese or Overweight Adults
ALAMEDA, Calif.--(BUSINESS WIRE)--Vivani Medical, Inc. (NASDAQ: VANI) (“Vivani” or the “Company”), a clinical-stage biopharmaceutical company developing miniature, ultra long-acting drug implants, today announced the successful administration of its first GLP-1 (exenatide) implant in the LIBERATE-1™ clinical trial. This milestone marks a critical step toward addressing one of healthcare's most pressing challenges: medication adherence in metabolic diseases including chronic weight management an.

Neutral
Business Wire
2 weeks ago
Vivani Medical Announces Intent to Spin Off Cortigent Neurostimulation Business
ALAMEDA, Calif.--(BUSINESS WIRE)--Vivani Medical, Inc. (NASDAQ: VANI) (“Vivani” or the “Company”), a clinical-stage biopharmaceutical company developing miniature, ultra long-acting drug implants, today announced that it intends to spin off Cortigent, Inc., a division that develops brain implant devices to help people recover critical body functions, as an independent publicly-traded company. The strategic goal of this transaction is to create two focused companies dedicated to driving current.

Positive
Benzinga
2 weeks ago
EXCLUSIVE: Vivani Medical To Spin Off Cortigent Neurostimulation Business To Create Better Focus On Individual Entities And Shareholder Value
On Wednesday, Vivani Medical, Inc. VANI said it intends to spin off Cortigent, Inc., a division that develops brain implant devices to help people recover critical body functions, as an independent publicly-traded company.

Neutral
Business Wire
3 months ago
Vivani Medical Announces Initiation of First in Human Clinical Trial with GLP-1 Implant in Obese and Overweight Individuals in Australia
ALAMEDA, Calif.--(BUSINESS WIRE)--Vivani Medical, Inc. (Nasdaq: VANI) (“Vivani” or the “Company”), an innovative biopharmaceutical company developing novel, ultra long-acting drug implants, today announced that screening and enrollment of the first-in-human clinical trial, known as LIBERATE-1™, has been initiated at two centers in Australia to investigate the safety, tolerability and full pharmacokinetic profile of an exenatide implant. This study is the first clinical application of the Compan.

Neutral
Business Wire
3 months ago
Vivani Medical to Present at the Innovation in Obesity Therapeutics Summit West Coast
ALAMEDA, Calif.--(BUSINESS WIRE)--Vivani Medical, Inc. (NASDAQ: VANI) (the “Company” or “Vivani”), an innovative biopharmaceutical company developing miniaturized, ultra long-acting drug implants, announced today that CEO Adam Mendelsohn, Ph.D., will present and participate in a panel discussion at the Innovation in Obesity Therapeutics Summit West Coast, taking place in San Diego, California, from December 10-12, 2024. Event details are as follows: Panel Discussion: The Obesity Race on the Man.

Charts implemented using Lightweight Charts™